Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
5.77
+0.10 (1.76%)
At close: Feb 21, 2025, 4:00 PM
5.81
+0.04 (0.69%)
After-hours: Feb 21, 2025, 5:21 PM EST
Company Description
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products.
At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications.
Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains.
These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
Anbio Biotechnology
| Country | Germany |
| Founded | 2021 |
| IPO Date | Feb 19, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Lau |
Contact Details
Address: Wilhelm Gutbrod Str 21B, 60437 Frankfurt am Main Germany | |
| Phone | +49 16 0962 47281 |
Stock Details
| Ticker Symbol | NNNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001982708 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael Lau | Chief Executive Officer |
| Suki Song | Chief Financial Officer |
| Chris Tian | Chief Business Officer |
| Cany Xu | Director |
| Nancy Hartzler | Independent Director (Appointee), Chair of Compensation Committee |
| Kenneth Li | Independent Director (Appointee), Chair of Audit Committee |
| David Hsu | Independent Director (Appointee), Chair of Nominating Committee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 424B4 | Prospectus |
| Feb 18, 2025 | EFFECT | Notice of Effectiveness |
| Feb 18, 2025 | CERT | Certification by an exchange approving securities for listing |
| Feb 14, 2025 | 8-A12B | Registration of securities |
| Feb 10, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 24, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 22, 2025 | FWP | Free Writing Prospectus |
| Jan 10, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 31, 2024 | F-1 | Registration statement for certain foreign private issuers |